MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461793 | Name: Penicillin G potassium
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Penicillin G is a β-lactam antibiotic. Penicillin G is a β-lactam antibiotic that is effective mainly for Gram-positive bacteria. It has MIC90 values of 0.03, 1, and 4 µg/ml for penicillin-susceptible, -intermediate, and -resistant strains of S. pneumoniae, respectively, and 16-128 µg/ml for various Bacteroides isolates in a broth dilution assay. Formulations containing penicillin G have been used for the treatment of bacterial infections and in livestock production. Penicillin G potassium has the same chemical structure as Picibanil (OK-432, OK432; OK 432) as shown in web page: https://chem.nlm.nih.gov/chemidplus/name/startswith/picibanil

Chemical Structure

Penicillin G potassium
Penicillin G potassium
CAS#113-98-4 (potassium)

Theoretical Analysis

MedKoo Cat#: 461793

Name: Penicillin G potassium

CAS#: 113-98-4 (potassium)

Chemical Formula: C16H17KN2O4S

Exact Mass: 333.0915

Molecular Weight: 372.48

Elemental Analysis: C, 51.59; H, 4.60; K, 10.50; N, 7.52; O, 17.18; S, 8.61

Price and Availability

Size Price Availability Quantity
500mg USD 60.00 Ready to ship
1g USD 90.00 Ready to ship
2g USD 150.00 Ready to ship
5g USD 350.00 Ready to ship
10g USD 550.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1538-09-6 (benzathine anhydrous) 113-98-4 (potassium) 6130-64-9 (procaine hydrate) Penicillin G-d5 K (d5 potassium) 3344-16-9 (hydrabamine)
Synonym
Penicillin G Potassium Salt; Benzylpenicillin
IUPAC/Chemical Name
potassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
InChi Key
IYNDLOXRXUOGIU-LQDWTQKMSA-M
InChi Code
InChI=1S/C16H18N2O4S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
SMILES Code
O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC(CC3=CC=CC=C3)=O)N1C2=O)[O-].[K+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in water
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2941.10.2000
More Info
Penicillin G potassium has the same chemical structure as Picibanil as shown in web page: Picibanil: https://chem.nlm.nih.gov/chemidplus/name/startswith/picibanil Penicillin G potassium: https://chem.nlm.nih.gov/chemidplus/rn/113-98-4
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#T20C02I11
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Penicillin G potassium is a fast-acting antibiotic; used to treat bacterial infections that affect the blood, heart, lungs, joints, and genital areas.
In vitro activity:
To investigate the effect of OK-432 on bladder cancer cells through TAMs, this study examined the apoptosis after T24 and EJ cells treated with various concentrations conditional medium for 24 hours, and then stained with Annexin-V and Propidium iodide, and analyzed using flow cytometer. In Figure 2A, the apoptosis rate of T24 cells which treated with 0, 0.1, 0.5, and 1 ke/ml OK-432 was 5.08%, 6.55%, 15.53%, and 23.2% respectively (Figure 2A), and the apoptosis rate of EJ cells was observed to increase shown dose-dependent (Figure 2B). 1 ke/ml OK-432 increased the apoptosis rate more significantly than control group (Figure 2C-D). Hence, this study validated that OK-432 prompted the bladder cancer cell apoptosis through TAMs. Reference: Asian Pac J Cancer Prev. 2015;16(11):4537-42. https://pubmed.ncbi.nlm.nih.gov/26107200/
In vivo activity:
PBS-treated C3H/HeN and C3H/HeJ mice had higher OVA-specific IgE and IgG1 levels in sera than those of OK-432-treated mice after OVA sensitization (Figure 3). On the other hand, PBS-treated C3H/HeN and C3H/HeJ mice had lower OVA-specific IgG2a levels in sera than those of OK-432-treated mice after OVA sensitization. In response to OVA, splenic CD3+ T cells of PBS-treated C3H/HeN and C3H/HeJ mice sensitized with OVA actually produced IL-4, whereas IL-4 production significantly decreased in OK-432-treated C3H/HeN and C3H/HeJ mice sensitized with OVA (Figure 4). Furthermore, IFN-γ production in response to OVA increased in the culture supernatants of splenic T cells from OK-432-treated C3H/HeN and C3H/HeJ mice sensitized with OVA. Reference: Med Sci (Basel). 2018 Dec; 6(4): 107. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313634/
Solvent mg/mL mM
Solubility
H2O 100.0 268.50
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 372.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Sci Rep. 2017 Feb 13;7:42145. doi: 10.1038/srep42145. PMID: 28191816; PMCID: PMC5304184. 2. Tian YF, Tang K, Guan W, Yang T, Xu H, Zhuang QY, Ye ZQ. OK-432 Suppresses Proliferation and Metastasis by Tumor Associated Macrophages in Bladder Cancer. Asian Pac J Cancer Prev. 2015;16(11):4537-42. doi: 10.7314/apjcp.2015.16.11.4537. PMID: 26107200. 3. Aoi N, Morikura I, Fuchiwaki T, Yamada T, Prokopakis E, Kawauchi H. OK-432 Administration Inhibits Murine Allergic Rhinitis at the Induction Phase, through the Macrophage Activation with TLR2 Signaling Pathway. Med Sci (Basel). 2018 Nov 26;6(4):107. doi: 10.3390/medsci6040107. PMID: 30486312; PMCID: PMC6313634. 4. Wu CJ, Tseng PH, Chan CC, Quon S, Chen LC, Kuo ML. OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma. J Immunol Res. 2018 Oct 8;2018:1697276. doi: 10.1155/2018/1697276. PMID: 30402504; PMCID: PMC6196917.
In vitro protocol:
1. Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Sci Rep. 2017 Feb 13;7:42145. doi: 10.1038/srep42145. PMID: 28191816; PMCID: PMC5304184. 2. Tian YF, Tang K, Guan W, Yang T, Xu H, Zhuang QY, Ye ZQ. OK-432 Suppresses Proliferation and Metastasis by Tumor Associated Macrophages in Bladder Cancer. Asian Pac J Cancer Prev. 2015;16(11):4537-42. doi: 10.7314/apjcp.2015.16.11.4537. PMID: 26107200.
In vivo protocol:
1. Aoi N, Morikura I, Fuchiwaki T, Yamada T, Prokopakis E, Kawauchi H. OK-432 Administration Inhibits Murine Allergic Rhinitis at the Induction Phase, through the Macrophage Activation with TLR2 Signaling Pathway. Med Sci (Basel). 2018 Nov 26;6(4):107. doi: 10.3390/medsci6040107. PMID: 30486312; PMCID: PMC6313634. 2. Wu CJ, Tseng PH, Chan CC, Quon S, Chen LC, Kuo ML. OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma. J Immunol Res. 2018 Oct 8;2018:1697276. doi: 10.1155/2018/1697276. PMID: 30402504; PMCID: PMC6196917.
1: Sengul S, Kaygusuz I, Akin MM, Yalcin Ş, Karlidag T, Keles E, Arslan I. The effect of OK-432 (Picibanil) injection on the histopathology of nasal turbinate. J Laryngol Otol. 2015 Dec;129(12):1208-12. doi: 10.1017/S002221511500273X. Epub 2015 Oct 12. PubMed PMID: 26456255. 2: O'Brien B, Kesby G, Ogle R, Rieger I, Hyett JA. Treatment of Primary Fetal Hydrothorax with OK-432 (Picibanil): Outcome in 14 Fetuses and a Review of the Literature. Fetal Diagn Ther. 2015;37(4):259-66. doi: 10.1159/000363651. Epub 2015 Feb 14. PubMed PMID: 25721226. 3: Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017. PubMed PMID: 24509171. 4: Rebuffini E, Zuccarino L, Grecchi E, Carinci F, Merulla VE. Picibanil (OK-432) in the treatment of head and neck lymphangiomas in children. Dent Res J (Isfahan). 2012 Dec;9(Suppl 2):S192-6. doi: 10.4103/1735-3327.109752. PubMed PMID: 23814582; PubMed Central PMCID: PMC3692172. 5: Lanuza García A, Bañón Navarro R, Llorca Cardeñosa A, Delgado Navarro C. [Unsuccessful treatment with OK-432 picibanil for orbital lymphangioma]. Arch Soc Esp Oftalmol. 2012 Jan;87(1):17-9. doi: 10.1016/j.oftal.2011.05.022. Epub 2011 Dec 16. Spanish. PubMed PMID: 22248653. 6: Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011 Dec 15;129(12):2836-46. doi: 10.1002/ijc.25955. Epub 2011 Mar 29. PubMed PMID: 21448901. 7: Yoo C, Do HA, Jeong IG, Park H, Hwang JJ, Hong JH, Cho JS, Choo MS, Ahn H, Kim CS. Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line. J Korean Med Sci. 2010 Sep;25(9):1284-90. doi: 10.3346/jkms.2010.25.9.1284. Epub 2010 Aug 14. PubMed PMID: 20808670; PubMed Central PMCID: PMC2923792. 8: Cowie RV, Stone PR, Parry E, Jensen EC, Gunn AJ, Bennet L. Acute behavioral effects of intrapleural OK-432 (Picibanil) administration in preterm fetal sheep. Fetal Diagn Ther. 2009;25(3):304-13. doi: 10.1159/000235876. Epub 2009 Sep 22. PubMed PMID: 19776593. 9: Poldervaart MT, Breugem CC, Speleman L, Pasmans S. Treatment of lymphatic malformations with OK-432 (Picibanil): review of the literature. J Craniofac Surg. 2009 Jul;20(4):1159-62. doi: 10.1097/SCS.0b013e3181abb249. Review. PubMed PMID: 19553857. 10: Kim MG, Kim SG, Lee JH, Eun YG, Yeo SG. The therapeutic effect of OK-432 (picibanil) sclerotherapy for benign neck cysts. Laryngoscope. 2008 Dec;118(12):2177-81. doi: 10.1097/MLG.0b013e3181864acf. PubMed PMID: 19029851. 11: Subotic U, Hosie S, Waag KL, Reinshagen K. [Treatment of lymphangiomas with picibanil in the first year of life]. Klin Padiatr. 2008 Jul-Aug;220(4):248-52. doi: 10.1055/s-2008-1073158. German. PubMed PMID: 18654945. 12: Roh JL, Kim HS. Primary treatment of pediatric plunging ranula with nonsurgical sclerotherapy using OK-432 (Picibanil). Int J Pediatr Otorhinolaryngol. 2008 Sep;72(9):1405-10. doi: 10.1016/j.ijporl.2008.06.003. Epub 2008 Jul 9. Review. PubMed PMID: 18617276. 13: Woolley SL, Smith DR, Quine S. Adult cystic hygroma: successful use of OK-432 (Picibanil). J Laryngol Otol. 2008 Nov;122(11):1260-4. doi: 10.1017/S0022215107001132. Epub 2008 Apr 23. Review. PubMed PMID: 18430261. 14: Hashimoto M, Takashige K, Furuyashiki M, Yoshidome K, Sano R, Kawamura Y, Ijichi S, Morioka H, Koide H, Oku N, Moriya Y, Kusumoto S, Suda Y. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning. Int Immunopharmacol. 2008 Jan;8(1):12-9. Epub 2007 Oct 22. PubMed PMID: 18068095. 15: Knipping S, Goetze G, Neumann K, Bloching M. Sclerotherapy of cervical cysts with Picibanil (OK-432). Eur Arch Otorhinolaryngol. 2007 Apr;264(4):423-7. Epub 2006 Nov 3. PubMed PMID: 17082941. 16: Matsushita K, Abe T, Fujiwara T. OK-432 (Picibanil) sclerotherapy for recurrent dislocation of the temporomandibular joint in elderly edentulous patients: Case reports. Br J Oral Maxillofac Surg. 2007 Sep;45(6):511-3. Epub 2006 Oct 23. PubMed PMID: 17056162. 17: Alonso J, Barbier L, Alvarez J, Romo L, Martín JC, Arteagoitia I, Santamaría J. OK432 (picibanil) efficacy in an adult with cystic cervical lymphangioma. A case report. Med Oral Patol Oral Cir Bucal. 2005 Aug-Oct;10(4):362-6. English, Spanish. PubMed PMID: 16056191. 18: Horii Y, Iino Y, Maemura M, Horiguchi J, Morishita Y. Inhibitory effects of OK-432 (Picibanil) on cellular proliferation and adhesive capacity of breast carcinoma cells. Oncol Rep. 2005 Feb;13(2):289-94. PubMed PMID: 15643513. 19: Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004 Sep-Oct;24(5C):3295-301. Review. PubMed PMID: 15515424. 20: Tanaka K, Ohmori Y, Mohri Y, Tonouchi H, Suematsu M, Taguchi Y, Adachi Y, Kusunoki M. Successful treatment of refractory hepatic lymphorrhea after gastrectomy for early gastric cancer, using surgical ligation and subsequent OK-432 (Picibanil) sclerotherapy. Gastric Cancer. 2004;7(2):117-21. Review. PubMed PMID: 15224199.